Capstone Triton Financial Group LLC Has $325,000 Stock Holdings in GSK plc (NYSE:GSK)

Capstone Triton Financial Group LLC lowered its stake in shares of GSK plc (NYSE:GSK) by 14.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,450 shares of the pharmaceutical company’s stock after selling 1,409 shares during the period. Capstone Triton Financial Group LLC’s holdings in GSK were worth $325,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in GSK. 1832 Asset Management L.P. increased its position in GSK by 9.1% in the 1st quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock valued at $132,000 after buying an additional 257 shares in the last quarter. Personal CFO Solutions LLC increased its holdings in shares of GSK by 2.7% during the fourth quarter. Personal CFO Solutions LLC now owns 10,087 shares of the pharmaceutical company’s stock valued at $374,000 after acquiring an additional 263 shares in the last quarter. Boltwood Capital Management raised its position in shares of GSK by 2.5% during the second quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock worth $429,000 after purchasing an additional 270 shares during the period. J.W. Cole Advisors Inc. lifted its holdings in shares of GSK by 4.7% in the 1st quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company’s stock worth $261,000 after purchasing an additional 271 shares in the last quarter. Finally, First Affirmative Financial Network grew its position in GSK by 4.7% in the 2nd quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock valued at $245,000 after purchasing an additional 283 shares during the period. Institutional investors own 15.74% of the company’s stock.

GSK Trading Down 2.0 %

Shares of GSK stock opened at $40.80 on Friday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The company has a market capitalization of $84.55 billion, a price-to-earnings ratio of 14.78, a PEG ratio of 1.41 and a beta of 0.66. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92. The company has a 50-day simple moving average of $41.39 and a two-hundred day simple moving average of $41.70.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $9.95 billion for the quarter, compared to the consensus estimate of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. Research analysts anticipate that GSK plc will post 4.15 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Stockholders of record on Friday, August 16th will be given a dividend of $0.3843 per share. The ex-dividend date is Friday, August 16th. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a dividend yield of 3.77%. GSK’s dividend payout ratio (DPR) is currently 54.71%.

Wall Street Analyst Weigh In

GSK has been the topic of several research reports. Argus upgraded shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Citigroup upgraded shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. Jefferies Financial Group lifted their price target on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Finally, The Goldman Sachs Group began coverage on GSK in a report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.